{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclic+Estradiol&page=10",
    "query": {
      "intervention": "Cyclic Estradiol",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 333,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclic+Estradiol&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclic+Estradiol&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T03:40:35.558Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03432416",
      "title": "Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Women",
        "Female Contraception"
      ],
      "interventions": [
        {
          "name": "NES-E2 CVR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Premier Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 385,
      "start_date": "2018-02-12",
      "completion_date": "2021-12-14",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03432416"
    },
    {
      "nct_id": "NCT04224272",
      "title": "Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2+/HR+ Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ZW25 (Zanidatamab)",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2020-06-10",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 3,
      "location_summary": "Santa Monica, California • Nashville, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04224272"
    },
    {
      "nct_id": "NCT02422615",
      "title": "Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 726,
      "start_date": "2015-06-09",
      "completion_date": "2023-01-11",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422615"
    },
    {
      "nct_id": "NCT01475513",
      "title": "Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insulin Sensitivity",
        "Cardiovascular Risk",
        "Perimenopausal Disorder"
      ],
      "interventions": [
        {
          "name": "Ortho Cyclen®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2011-11",
      "completion_date": "2014-05-28",
      "has_results": true,
      "last_update_posted_date": "2018-08-08",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475513"
    },
    {
      "nct_id": "NCT00237042",
      "title": "Managing Temporomandibular Disorder (TMD) Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Temporomandibular Joint Disorders"
      ],
      "interventions": [
        {
          "name": "Self Management",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Targeted Self Management",
          "type": "BEHAVIORAL"
        },
        {
          "name": "20 mcg ethinyl estradiol and 100 mcg levonorgestrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 252,
      "start_date": "2005-10",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2011-07-11",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00237042"
    },
    {
      "nct_id": "NCT01560416",
      "title": "Fulvestrant With or Without Ganetespib in HR+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-06",
      "completion_date": "2016-06-26",
      "has_results": true,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Concord",
          "state": "New Hampshire"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01560416"
    },
    {
      "nct_id": "NCT07811232",
      "title": "A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Neoplasms",
        "Soft Tissue Sarcoma (STS)",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "AL58805",
          "type": "DRUG"
        },
        {
          "name": "AL8326",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advenchen Pharmaceuticals, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-09-01",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07811232"
    },
    {
      "nct_id": "NCT01250210",
      "title": "Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovulation Suppression"
      ],
      "interventions": [
        {
          "name": "levonorgestrel and ethinyl estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agile Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 123,
      "start_date": "2007-09",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250210"
    },
    {
      "nct_id": "NCT03685331",
      "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Advanced Breast Cancer",
        "BRCA2 Mutation",
        "BRCA1 Mutation"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2020-10-15",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03685331"
    },
    {
      "nct_id": "NCT04305236",
      "title": "Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasm",
        "Hormone Receptor Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2020-07-23",
      "completion_date": "2022-02-16",
      "has_results": true,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-11-19T03:40:35.558Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305236"
    }
  ]
}